Verastem Inc at H C Wainwright BioConnect Conference (Virtual) Transcript
Good afternoon, everyone, and thank you for joining the H.C. Wainwright 2021 BioConnect Conference. My name is Sean Lee, and I'm an equity research analyst at the firm. While we are virtual this year, we are confident we are going to be able to provide value to you with over 375 companies presenting at this conference.
Today, I am hosting a fireside chat with the CEO of Verastem Oncology, Mr. Brian Stuglik. Brian, to start with off and for the benefit of the investors who aren't -- may not be familiar with Verastem, could you give us some background on the company and its product pipeline?
Sure. Thank you, Sean, and thank you to H.C. Wainwright for hosting the virtual conference. So Verastem is a Boston-based company. We were founded in 2010, and we're as a research-based organization. In 2020, we went through a pretty significant transformation of the company. Beginning in January of 2020, we in-licensed what we now
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |